The effect of fluvoxamine on the pharmacokinetics and pharmacodynamics of buspirone

@article{Lamberg1998TheEO,
  title={The effect of fluvoxamine on the pharmacokinetics and pharmacodynamics of buspirone},
  author={Tommi S. Lamberg and Kari T. Kivistö and Jouko Laitila and K M{\aa}rtensson and Pertti J. Neuvonen},
  journal={European Journal of Clinical Pharmacology},
  year={1998},
  volume={54},
  pages={761-766}
}
AbstractObjective: The effects of fluvoxamine, a selective serotonin (5-HT) reuptake inhibitor antidepressant, on the pharmacokinetics and pharmacodynamics of buspirone, a non-benzodiazepine anxiolytic agent, were investigated. Methods: In a randomized, placebo-controlled, two-phase cross-over study, ten healthy volunteers took either 100 mg fluvoxamine or matched placebo orally once daily for 5 days. On day 6, 10 mg buspirone was taken orally. Plasma concentrations of buspirone and its active… 

Effect of the novel anxiolytic drug deramciclane on the pharmacokinetics and pharmacodynamics of the CYP3A4 probe drug buspirone

Deramciclane does not inhibit CYP3A4 activity as measured by buspirone pharmacokinetics, and there were no indications of relevant pharmacodynamic interaction after multiple doses of deramcIClane and a single dose of buspir one.

The Influence of Fluvoxamine Administration on Glibenclamide Pharmacokinetics After Multiple Oral Dosing in Rats

Results indicated that following the single dose administration, glibenclamide C„, was 415±1 69ng/ml, T„„ was 3.7±1.4h, t, and fluvoxamine, a potent inhibitor of cytochrome P450 (CYP) isoenzymes may be coadministered with glibanclamide.

Metabolism of Ramelteon in Human Liver Microsomes and Correlation with the Effect of Fluvoxamine on Ramelteon Pharmacokinetics

In vitro metabolism data suggest that there may be a limit on the magnitude of DDI that can be estimated from in vitro data, and the example of the fluvoxamine-ramelteon DDI offers a unique example wherein one drug can simultaneously inhibit multiple enzymatic pathways of a second drug.

Effects of cytochrome P450 (CYP) 3A4 inhibitors on the anxiolytic action of tandospirone in rat contextual conditioned fear

Pharmacokinetics of Haloperidol

In vivo pharmacogenetic studies have indicated that the metabolism and disposition of haloperidol may be regulated by genetically determined polymorphic CYP2D6 activity, however, these findings appear to contradict those from studies in vitro with human liver microsomes and from studies of drug interactions in vivo.

A drug–drug interaction study to assess the effect of the CYP1A2 inhibitor fluvoxamine on the pharmacokinetics of dovitinib (TKI258) in patients with advanced solid tumors

Dovitinib should, therefore, not be co-administered with moderate and strong CYP1A2 inhibitors, without dose reduction, and patients are at risk of dovit inib related toxicity.

Pharmacokinetic interaction between tandospirone and fluvoxamine in the rat contextual conditioned fear stress model and its functional consequence: Involvement of cytochrome P450 3A4

The pharmacokinetic interaction between tandospirone and fluvoxamine is clarified and their combined effect in the rat anxiety model is evaluated.

Hypnotics and sedatives

Selective serotonin reuptake inhibitor drug interactions in patients receiving statins.

  • C. Andrade
  • Medicine, Biology
    The Journal of clinical psychiatry
  • 2014
Elderly patients commonly receive statin drugs for the primary or secondary prevention of cardiovascular and cerebrovascular events and SSRIs for the treatment of depression, anxiety, or other conditions, and a detailed literature review of statin metabolism and of SSRI effects on CYP enzymes suggests that escitalopram, citaloprams, and paroxetine are almost certain to be safe with all statins.

References

SHOWING 1-10 OF 20 REFERENCES

The effect of chronic fluvoxamine on hormonal and psychological responses to buspirone in normal volunteers

The blunting of GH and psychological responses suggest that 5-HT1A receptor function is reduced by chronic fluvoxamine treatment, which is likely to be due to inhibition of first pass liver metabolism by fluv oxamine acting on the cytochrome P-450 system.

A Study of Pharmacokinetic Interaction Between Buspirone and Alprazolam at Steady State

The results of this study suggest that coadministration of buspirone and alprazolam did not markedly affect the steady‐state pharmacokinetics of either drug.

Metabolism and disposition of buspirone.

Metabolism of the antianxiety drug buspirone in human subjects.

The metabolism of an oral dose of the antianxiety drug buspirone labeled with 14C/15N was studied in human subjects to facilitate structural characterization of the metabolites by mass spectrometry.

Fluvoxamine is a potent inhibitor of cytochrome P4501A2.

Fluvoxamine. A review of global drug-drug interaction data.

Clinical symptoms were infrequent and varied widely; no symptom clusters were identified; those agents metabolised by cytochrome P450 1A2 isoenzyme appear most likely to be involved in drug-drug interactions with fluvoxamine.

In vitro metabolism of the antianxiety drug buspirone as a predictor of its metabolism in vivo.

Hepatocytes and phenobarbital- induced rat liver microsomes were better predictors of in vivo metabolism of buspirone than non-induced rat livermicrosomes and these in vitro systems should provide excellent models for studying the metabolism of other azaspirodecanedione-containing drugs.

An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression.

Clinical evidence is provided suggesting that buspirone augmentation may be a useful clinical alternative in depressed patients who fail to respond to a serotonin reuptake inhibitor.

Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole